At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 607 enrolled
Drug / intervention
bevacizumab [Avastin]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Study of the Effect of Avastin Plus Gemcitabine and Erlotinib Compared With Placebo Plus Gemcitabine and Erlotinib on Overall Survival in Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 3 clinical trial evaluating bevacizumab [Avastin] for Pancreatic Cancer. Completed, enrolled 607 participants across 101 sites in 21 countries.
Detailed Summary
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesAustralia, Austria, Belgium, Canada, China, Czechia, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Peru, Poland, Singapore, South Africa, Spain, Sweden, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
Primary CompletionOct 2008
First PostedOct 2010
TodayJul 2026
First PostedOct 5, 2010
Enrollment StartJul 1, 2005
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.7 years ago
Interventions
bevacizumab [Avastin]drug
Intervenous repeating dose